JP2009509910A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009509910A5 JP2009509910A5 JP2008503207A JP2008503207A JP2009509910A5 JP 2009509910 A5 JP2009509910 A5 JP 2009509910A5 JP 2008503207 A JP2008503207 A JP 2008503207A JP 2008503207 A JP2008503207 A JP 2008503207A JP 2009509910 A5 JP2009509910 A5 JP 2009509910A5
- Authority
- JP
- Japan
- Prior art keywords
- hdac6
- moiety
- substituted
- amino acids
- branched
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100022537 Histone deacetylase 6 Human genes 0.000 claims 66
- 101000899330 Homo sapiens Histone deacetylase 6 Proteins 0.000 claims 66
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 claims 59
- 150000001413 amino acids Chemical class 0.000 claims 38
- 210000004180 plasmocyte Anatomy 0.000 claims 37
- 210000004027 cell Anatomy 0.000 claims 36
- 150000001875 compounds Chemical class 0.000 claims 35
- 239000000203 mixture Substances 0.000 claims 35
- 125000003118 aryl group Chemical group 0.000 claims 26
- 125000001072 heteroaryl group Chemical group 0.000 claims 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims 23
- 239000003112 inhibitor Substances 0.000 claims 22
- 125000001931 aliphatic group Chemical group 0.000 claims 20
- 238000000034 method Methods 0.000 claims 20
- 229910052739 hydrogen Inorganic materials 0.000 claims 19
- 239000001257 hydrogen Substances 0.000 claims 19
- 230000017854 proteolysis Effects 0.000 claims 16
- 125000002252 acyl group Chemical group 0.000 claims 15
- 125000002015 acyclic group Chemical group 0.000 claims 14
- 125000004122 cyclic group Chemical group 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 208000035475 disorder Diseases 0.000 claims 13
- -1 heteroaliphatic Chemical group 0.000 claims 12
- 150000002431 hydrogen Chemical group 0.000 claims 12
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 150000007523 nucleic acids Chemical class 0.000 claims 12
- 229920001184 polypeptide Polymers 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 230000021736 acetylation Effects 0.000 claims 11
- 230000001413 cellular effect Effects 0.000 claims 11
- 238000006640 acetylation reaction Methods 0.000 claims 10
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 125000006239 protecting group Chemical group 0.000 claims 9
- 230000034512 ubiquitination Effects 0.000 claims 9
- 238000010798 ubiquitination Methods 0.000 claims 9
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 125000003282 alkyl amino group Chemical group 0.000 claims 8
- 230000006907 apoptotic process Effects 0.000 claims 8
- 125000005110 aryl thio group Chemical group 0.000 claims 8
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 7
- 125000004414 alkyl thio group Chemical group 0.000 claims 7
- 125000004104 aryloxy group Chemical group 0.000 claims 7
- 125000004663 dialkyl amino group Chemical group 0.000 claims 7
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- 239000003207 proteasome inhibitor Substances 0.000 claims 7
- 238000012360 testing method Methods 0.000 claims 7
- 102000004091 Caspase-8 Human genes 0.000 claims 6
- 108090000538 Caspase-8 Proteins 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 claims 6
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 claims 6
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 6
- 125000002723 alicyclic group Chemical group 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000005368 heteroarylthio group Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 238000011282 treatment Methods 0.000 claims 6
- 102100039869 Histone H2B type F-S Human genes 0.000 claims 5
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 230000001404 mediated effect Effects 0.000 claims 5
- OVOUKWFJRHALDD-UHFFFAOYSA-N 2-[2-(2-acetyloxyethoxy)ethoxy]ethyl acetate Chemical compound CC(=O)OCCOCCOCCOC(C)=O OVOUKWFJRHALDD-UHFFFAOYSA-N 0.000 claims 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims 4
- 206010006002 Bone pain Diseases 0.000 claims 4
- 208000037147 Hypercalcaemia Diseases 0.000 claims 4
- 206010061598 Immunodeficiency Diseases 0.000 claims 4
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 4
- 108060003951 Immunoglobulin Proteins 0.000 claims 4
- 208000034578 Multiple myelomas Diseases 0.000 claims 4
- 208000003076 Osteolysis Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 208000001647 Renal Insufficiency Diseases 0.000 claims 4
- 102000004243 Tubulin Human genes 0.000 claims 4
- 108090000704 Tubulin Proteins 0.000 claims 4
- 230000002776 aggregation Effects 0.000 claims 4
- 238000004220 aggregation Methods 0.000 claims 4
- 208000036878 aneuploidy Diseases 0.000 claims 4
- 231100001075 aneuploidy Toxicity 0.000 claims 4
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 4
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical group C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 4
- 102000013035 dynein heavy chain Human genes 0.000 claims 4
- 108060002430 dynein heavy chain Proteins 0.000 claims 4
- 230000001747 exhibiting effect Effects 0.000 claims 4
- 230000000148 hypercalcaemia Effects 0.000 claims 4
- 208000030915 hypercalcemia disease Diseases 0.000 claims 4
- 230000007813 immunodeficiency Effects 0.000 claims 4
- 102000018358 immunoglobulin Human genes 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 201000006370 kidney failure Diseases 0.000 claims 4
- 208000029791 lytic metastatic bone lesion Diseases 0.000 claims 4
- 230000003211 malignant effect Effects 0.000 claims 4
- 230000017074 necrotic cell death Effects 0.000 claims 4
- 208000004235 neutropenia Diseases 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 206010043554 thrombocytopenia Diseases 0.000 claims 4
- 229940104230 thymidine Drugs 0.000 claims 4
- 102000003964 Histone deacetylase Human genes 0.000 claims 3
- 108090000353 Histone deacetylase Proteins 0.000 claims 3
- BHUZLJOUHMBZQY-YXQOSMAKSA-N N-[4-[(2R,4R,6S)-4-[[(4,5-diphenyl-2-oxazolyl)thio]methyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]phenyl]-N'-hydroxyoctanediamide Chemical group C1=CC(CO)=CC=C1[C@H]1O[C@@H](C=2C=CC(NC(=O)CCCCCCC(=O)NO)=CC=2)O[C@@H](CSC=2OC(=C(N=2)C=2C=CC=CC=2)C=2C=CC=CC=2)C1 BHUZLJOUHMBZQY-YXQOSMAKSA-N 0.000 claims 3
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 claims 3
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims 3
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 208000007502 anemia Diseases 0.000 claims 3
- 229960001467 bortezomib Drugs 0.000 claims 3
- 229950002736 marizomib Drugs 0.000 claims 3
- 230000002797 proteolythic effect Effects 0.000 claims 3
- NGWSFRIPKNWYAO-SHTIJGAHSA-N salinosporamide A Chemical compound C([C@@H]1[C@H](O)[C@]23C(=O)O[C@]2([C@H](C(=O)N3)CCCl)C)CCC=C1 NGWSFRIPKNWYAO-SHTIJGAHSA-N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 108091030071 RNAI Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- 108010005705 Ubiquitinated Proteins Proteins 0.000 claims 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 230000001640 apoptogenic effect Effects 0.000 claims 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims 2
- 230000022131 cell cycle Effects 0.000 claims 2
- 210000004748 cultured cell Anatomy 0.000 claims 2
- 230000008021 deposition Effects 0.000 claims 2
- 230000003831 deregulation Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000009368 gene silencing by RNA Effects 0.000 claims 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 238000010348 incorporation Methods 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 230000009467 reduction Effects 0.000 claims 2
- 230000022983 regulation of cell cycle Effects 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 108091005703 transmembrane proteins Proteins 0.000 claims 2
- 102000035160 transmembrane proteins Human genes 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 229960003048 vinblastine Drugs 0.000 claims 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 2
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 claims 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims 1
- 208000011403 Alexander disease Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 1
- 102000014461 Ataxins Human genes 0.000 claims 1
- 108010078286 Ataxins Proteins 0.000 claims 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 101800001415 Bri23 peptide Proteins 0.000 claims 1
- 102400000107 C-terminal peptide Human genes 0.000 claims 1
- 101800000655 C-terminal peptide Proteins 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- 108050001049 Extracellular proteins Proteins 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 1
- 108010069236 Goserelin Proteins 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
- 208000018839 Wilson disease Diseases 0.000 claims 1
- 229940022663 acetate Drugs 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- 125000005122 aminoalkylamino group Chemical group 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 229960002932 anastrozole Drugs 0.000 claims 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims 1
- 210000001130 astrocyte Anatomy 0.000 claims 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 1
- 239000003124 biologic agent Substances 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 229960004117 capecitabine Drugs 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 229960000255 exemestane Drugs 0.000 claims 1
- 208000019995 familial amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 229960001751 fluoxymesterone Drugs 0.000 claims 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 claims 1
- 229960002258 fulvestrant Drugs 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 229960003690 goserelin acetate Drugs 0.000 claims 1
- 210000003780 hair follicle Anatomy 0.000 claims 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
- 229940125697 hormonal agent Drugs 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000011283 initial treatment period Methods 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 150000002596 lactones Chemical class 0.000 claims 1
- 229960003881 letrozole Drugs 0.000 claims 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 230000035800 maturation Effects 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 claims 1
- 230000023837 negative regulation of proteolysis Effects 0.000 claims 1
- 210000001178 neural stem cell Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims 1
- 229960003978 pamidronic acid Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 238000002203 pretreatment Methods 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 239000012217 radiopharmaceutical Substances 0.000 claims 1
- 229960004622 raloxifene Drugs 0.000 claims 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 claims 1
- 229950007866 tanespimycin Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229960005026 toremifene Drugs 0.000 claims 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
- 229960004276 zoledronic acid Drugs 0.000 claims 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims 1
- 0 *C(C1)OC(*)OC1c1ccccc1 Chemical compound *C(C1)OC(*)OC1c1ccccc1 0.000 description 4
- OSERBMSTMDQOTG-UHFFFAOYSA-N ONC(CCCCCCC(NC(OC(CSC1OC(c2ccccc2)=C(c2ccccc2)N1)C1)OC1c1ccccc1)=O)=O Chemical compound ONC(CCCCCCC(NC(OC(CSC1OC(c2ccccc2)=C(c2ccccc2)N1)C1)OC1c1ccccc1)=O)=O OSERBMSTMDQOTG-UHFFFAOYSA-N 0.000 description 1
- NODPXUVYYCNOFZ-UHFFFAOYSA-N [O-][N+](c1ccc(C2OC(NC(CCCCCCC(NO)=O)=O)OC(CSC(OC3c4ccccc4)=NC3C3C=CC=CC3)C2)cc1)=O Chemical compound [O-][N+](c1ccc(C2OC(NC(CCCCCCC(NO)=O)=O)OC(CSC(OC3c4ccccc4)=NC3C3C=CC=CC3)C2)cc1)=O NODPXUVYYCNOFZ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66447005P | 2005-03-22 | 2005-03-22 | |
| US60/664,470 | 2005-03-22 | ||
| PCT/US2006/010676 WO2006102557A2 (en) | 2005-03-22 | 2006-03-22 | Treatment of protein degradation disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012266681A Division JP2013053157A (ja) | 2005-03-22 | 2012-12-05 | タンパク質分解障害の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009509910A JP2009509910A (ja) | 2009-03-12 |
| JP2009509910A5 true JP2009509910A5 (https=) | 2009-05-21 |
| JP5744376B2 JP5744376B2 (ja) | 2015-07-08 |
Family
ID=37024659
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008503207A Expired - Lifetime JP5744376B2 (ja) | 2005-03-22 | 2006-03-22 | タンパク質分解障害の治療 |
| JP2012266681A Withdrawn JP2013053157A (ja) | 2005-03-22 | 2012-12-05 | タンパク質分解障害の治療 |
| JP2014180860A Withdrawn JP2014224158A (ja) | 2005-03-22 | 2014-09-05 | タンパク質分解障害の治療 |
| JP2017141932A Pending JP2017190338A (ja) | 2005-03-22 | 2017-07-21 | タンパク質分解障害の治療 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012266681A Withdrawn JP2013053157A (ja) | 2005-03-22 | 2012-12-05 | タンパク質分解障害の治療 |
| JP2014180860A Withdrawn JP2014224158A (ja) | 2005-03-22 | 2014-09-05 | タンパク質分解障害の治療 |
| JP2017141932A Pending JP2017190338A (ja) | 2005-03-22 | 2017-07-21 | タンパク質分解障害の治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US8999289B2 (https=) |
| EP (3) | EP2491926B1 (https=) |
| JP (4) | JP5744376B2 (https=) |
| CN (1) | CN101495116A (https=) |
| AU (1) | AU2006226861B2 (https=) |
| CA (2) | CA2601706C (https=) |
| SG (1) | SG171690A1 (https=) |
| WO (1) | WO2006102557A2 (https=) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
| US20030129724A1 (en) | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
| US7244853B2 (en) | 2001-05-09 | 2007-07-17 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
| CN101495116A (zh) | 2005-03-22 | 2009-07-29 | 哈佛大学校长及研究员协会 | 蛋白降解病症的治疗 |
| EP1874296A4 (en) * | 2005-04-29 | 2010-06-30 | Kosan Biosciences Inc | METHOD FOR THE TREATMENT OF SEVERAL MYELOMES USING 17-AAG OR 17-AG OR PRODRUGS OR ALL |
| BRPI0609861A2 (pt) * | 2005-04-29 | 2010-05-11 | Kosan Biosciences Inc | uso de 17-aag ou 17-ag ou um pró-fármaco de ambos em combinação com um inibidor de proteassoma na preparação de formulações farmacêuticas para tratar mieloma múltiplo |
| AU2006278718B2 (en) | 2005-08-03 | 2010-10-07 | Secura Bio Inc. | Use of HDAC inhibitors for the treatment of myeloma |
| CA2636596A1 (en) * | 2005-11-04 | 2007-05-18 | James Pluda | Method of treating cancers with saha and pemetrexed |
| AU2007214458C1 (en) * | 2006-02-14 | 2012-12-06 | Dana-Farber Cancer Institute, Inc. | Histone deacetylase inhibitors |
| AU2007345292B2 (en) | 2006-02-14 | 2013-10-31 | Dana-Farber Cancer Institute, Inc. | Bifunctional histone deacetylase inhibitors |
| CA2654540C (en) * | 2006-05-03 | 2017-01-17 | President And Fellows Of Harvard College | Histone deacetylase and tubulin deacetylase inhibitors |
| WO2008054767A2 (en) * | 2006-10-30 | 2008-05-08 | University Of Southern California | N4 modifications of pyrimidine analogs and uses thereof |
| CN101528037A (zh) * | 2006-11-03 | 2009-09-09 | 默克公司 | 使用saha和硼替佐米治疗多发性骨髓瘤的方法 |
| US8754094B2 (en) * | 2007-08-15 | 2014-06-17 | The Research Foundation Of State University Of New York | Methods for heat shock protein dependent cancer treatment |
| US20110118274A1 (en) * | 2007-08-23 | 2011-05-19 | Cornell Research Foundation, Inc. | Proteasome inhibitors and their use in treating pathogen infection and cancer |
| WO2009152462A2 (en) * | 2008-06-12 | 2009-12-17 | The Board Of Trustees Of The University Of Illinois | Method of regulating cell growth using a proteasome inhibitor |
| RU2515611C2 (ru) * | 2008-07-23 | 2014-05-20 | Президент Энд Феллоуз Оф Гарвард Колледж | Ингибиторы деацетилазы и их применение |
| US20120142634A1 (en) * | 2008-11-10 | 2012-06-07 | Mount Sinai School Of Medicine Of New York University | Method of Treating Cancer with a Combination of a Proteasome Inhibitor and Salubrinal |
| CA2767697C (en) * | 2009-07-06 | 2014-10-14 | Memorial Sloan-Kettering Cancer Center | Hdac 6 inhibitor-based methods for treating cancer |
| WO2011019393A2 (en) | 2009-08-11 | 2011-02-17 | President And Fellows Of Harvard College | Class- and isoform-specific hdac inhibitors and uses thereof |
| CN108404123A (zh) * | 2010-01-15 | 2018-08-17 | 康奈尔大学 | 降低细胞内蛋白质水平的方法 |
| TWI600638B (zh) | 2010-01-22 | 2017-10-01 | 艾斯特隆製藥公司 | 作爲蛋白質去乙醯酶抑制劑之反式醯胺化合物及其使用方法 |
| AU2011242988B2 (en) * | 2010-04-19 | 2013-02-07 | Sri International | Compositions and method for the treatment of multiple myeloma |
| EP2625264B1 (en) | 2010-10-08 | 2022-12-07 | Terumo BCT, Inc. | Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions |
| BR112013011868A2 (pt) | 2010-11-16 | 2016-08-23 | Acetylon Pharmaceuticals Inc | compostos de pirimidina hidróxi amida como inibidores da proteína desacetilase, composição farmacêutica e uso dos referidos compostos |
| PT2678679T (pt) * | 2011-02-24 | 2017-04-07 | Basilea Pharmaceutica Ag | Utilização de tubulina acetilada como um biomarcador da resposta farmacológica a furazanobenzimidazolos |
| EP2508510A1 (en) | 2011-04-06 | 2012-10-10 | Ikerchem, S.L. | Hydroxyphenyl pyrrole compounds containing an hydroxamic acid as hdac inhibitors and medicinal applications thereof |
| GB201113538D0 (en) | 2011-08-04 | 2011-09-21 | Karobio Ab | Novel estrogen receptor ligands |
| EP2839037B1 (en) * | 2012-04-19 | 2018-12-26 | Acetylon Pharmaceuticals, Inc. | Biomarkers to identify patients that will respond to treatment and treating such patients |
| CA2888803A1 (en) * | 2012-11-05 | 2014-05-08 | Jooeun Bae | Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions |
| WO2014107655A1 (en) * | 2013-01-07 | 2014-07-10 | St. Jude Children's Research Hospital | Use of small molecule unfolder protein response modulators to treat tumors with active sonic hedgehog (ssh) signaling due to smoothened (smo) mutation |
| NZ714283A (en) | 2013-05-10 | 2020-04-24 | Karus Therapeutics Ltd | Novel histone deacetylase inhibitors |
| EP3021874B1 (en) * | 2013-07-18 | 2022-04-27 | The University of Hong Kong | Methods for classifying pleural fluid |
| ES2929576T3 (es) | 2013-10-08 | 2022-11-30 | Acetylon Pharmaceuticals Inc | Combinaciones de inhibidores de histona deacetilasa 6 y el inhibidor de Her2 lapatinib para el uso en el tratamiento del cáncer de mama |
| WO2015054474A1 (en) | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors |
| US10660890B2 (en) | 2013-10-24 | 2020-05-26 | National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) | Treatment of polycystic diseases with an HDAC6 inhibitor |
| JP6633522B2 (ja) | 2013-11-16 | 2020-01-22 | テルモ ビーシーティー、インコーポレーテッド | バイオリアクターにおける細胞増殖 |
| CR20160308A (es) | 2013-12-03 | 2016-11-08 | Acetylon Pharmaceuticals Inc | Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores |
| US9464073B2 (en) | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
| WO2015148704A1 (en) | 2014-03-25 | 2015-10-01 | Terumo Bct, Inc. | Passive replacement of media |
| SG11201700094TA (en) | 2014-07-07 | 2017-02-27 | Acetylon Pharmaceuticals Inc | Treatment of leukemia with histone deacetylase inhibitors |
| US20160090569A1 (en) | 2014-09-26 | 2016-03-31 | Terumo Bct, Inc. | Scheduled Feed |
| US10365280B2 (en) | 2014-10-02 | 2019-07-30 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating malignancies |
| GB201419264D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| GB201419228D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| US9937174B2 (en) | 2014-12-05 | 2018-04-10 | University of Modena and Reggio Emilia | Combinations of histone deacetylase inhibitors and bendamustine |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| PL3244909T3 (pl) * | 2015-01-14 | 2020-04-30 | Université D'aix-Marseille | Inhibitory proteasomu do leczenia zaburzenia związanego z nagromadzeniem nieuszkodzonego, nieprawidłowego białka lub raka |
| SG11201708622UA (en) | 2015-02-02 | 2017-11-29 | Forma Therapeutics Inc | 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors |
| WO2016126726A1 (en) | 2015-02-02 | 2016-08-11 | Forma Therapeutics, Inc. | Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors |
| US10272084B2 (en) | 2015-06-01 | 2019-04-30 | Regenacy Pharmaceuticals, Llc | Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy |
| AR104935A1 (es) | 2015-06-08 | 2017-08-23 | Acetylon Pharmaceuticals Inc | Formas cristalinas de un inhibidor de histona deacetilasa |
| AR105812A1 (es) | 2015-06-08 | 2017-11-15 | Acetylon Pharmaceuticals Inc | Métodos para la preparación de inhibidores de proteína deacetilasa |
| WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| EP3445364A4 (en) | 2016-04-19 | 2019-11-27 | Acetylon Pharmaceuticals, Inc. | HDAC INHIBITORS, ONLY OR IN COMBINATION WITH BTK INHIBITORS, FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| JP7034949B2 (ja) | 2016-05-25 | 2022-03-14 | テルモ ビーシーティー、インコーポレーテッド | 細胞の増殖 |
| GB201609786D0 (en) * | 2016-06-03 | 2016-07-20 | Karus Therapeutics Ltd | Compounds and method of use |
| US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
| US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
| EP3472131B1 (en) | 2016-06-17 | 2020-02-19 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
| US11324744B2 (en) | 2016-08-08 | 2022-05-10 | Acetylon Pharmaceuticals Inc. | Methods of use and pharmaceutical combinations of histone deacetylase inhibitors and CD20 inhibitory antibodies |
| WO2018064589A1 (en) | 2016-09-29 | 2018-04-05 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation using a mutant e3 ubiquitin ligase |
| CN108239656A (zh) * | 2016-12-27 | 2018-07-03 | 天津天锐生物科技有限公司 | 一种小分子药物控制的蛋白功能开关系统 |
| EP3576745B1 (en) * | 2017-01-31 | 2022-06-08 | The Board of Trustees of the Leland Stanford Junior University | Agents that inhibit ngly1 and methods of use thereof |
| US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
| US12234441B2 (en) | 2017-03-31 | 2025-02-25 | Terumo Bct, Inc. | Cell expansion |
| CN117247899A (zh) | 2017-03-31 | 2023-12-19 | 泰尔茂比司特公司 | 细胞扩增 |
| EP4717317A2 (en) | 2017-06-20 | 2026-04-01 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| CN118108706A (zh) | 2017-09-04 | 2024-05-31 | C4医药公司 | 戊二酰亚胺 |
| CN111278816B (zh) | 2017-09-04 | 2024-03-15 | C4医药公司 | 二氢喹啉酮 |
| CN118206529A (zh) | 2017-09-04 | 2024-06-18 | C4医药公司 | 二氢苯并咪唑酮 |
| EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
| JP2021512165A (ja) | 2018-01-29 | 2021-05-13 | コグノス・セラピューティクス・インコーポレイテッド | ボルテゾミブの腫瘍内送達 |
| JP2021519337A (ja) | 2018-03-26 | 2021-08-10 | シー４ セラピューティクス， インコーポレイテッド | Ｉｋａｒｏｓの分解のためのセレブロン結合剤 |
| CN119751456A (zh) | 2018-04-16 | 2025-04-04 | C4医药公司 | 螺环化合物 |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| WO2020181232A1 (en) | 2019-03-06 | 2020-09-10 | C4 Therapeutics, Inc. | Heterocyclic compounds for medical treatment |
| MX2022003490A (es) | 2019-09-27 | 2022-04-25 | Takeda Pharmaceuticals Co | Derivados de 2-isoindol-1,3,4-oxadiazol utiles como inhibidores de la histona desacetilasa 6 (hdac6). |
| AU2020412324A1 (en) | 2019-12-26 | 2022-07-07 | Centre D'etude Des Cellules Souches (Cecs) | Combination of a proteasome inhibitor and a HDAC inhibitor and its use for the treatment of genetic diseases linked to a protein conformational disorder |
| GB2619893A (en) | 2021-03-23 | 2023-12-20 | Terumo Bct Inc | Cell capture and expansion |
| US12152699B2 (en) | 2022-02-28 | 2024-11-26 | Terumo Bct, Inc. | Multiple-tube pinch valve assembly |
| PL247748B1 (pl) * | 2022-03-18 | 2025-08-25 | Inst Chemii Bioorganicznej Polskiej Akademii Nauk | Związek niskocząsteczkowy do zastosowania w leczeniu ataksji rdzeniowo-móżdżkowej typu 3 |
| USD1099116S1 (en) | 2022-09-01 | 2025-10-21 | Terumo Bct, Inc. | Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device |
| EP4410284A1 (en) | 2023-02-02 | 2024-08-07 | Apteeus | Compound and method for the treatment of zellweger spectrum disorder |
Family Cites Families (147)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US523781A (en) * | 1894-07-31 | Ice-cream freezer | ||
| HU165117B (https=) | 1971-08-12 | 1974-06-28 | ||
| US4160866A (en) | 1976-04-30 | 1979-07-10 | Imperial Chemical Industries Limited | Carbamates |
| DE3242252A1 (de) | 1982-11-15 | 1984-05-17 | Bayer Ag, 5090 Leverkusen | Heterocyclisch substituierte hydroxyalkyl-azolyl-derivate |
| NL194579C (nl) | 1983-01-21 | 2002-08-05 | Schering Ag | Diagnostisch middel. |
| US4631211A (en) | 1985-03-25 | 1986-12-23 | Scripps Clinic & Research Foundation | Means for sequential solid phase organic synthesis and methods using the same |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4608390A (en) | 1985-04-26 | 1986-08-26 | Abbott Laboratories | Lipoxygenase inhibiting compounds |
| US4833080A (en) | 1985-12-12 | 1989-05-23 | President And Fellows Of Harvard College | Regulation of eucaryotic gene expression |
| CA1319101C (en) | 1986-09-03 | 1993-06-15 | Marta Iris Sabara | Rotavirus nucleocapsid protein with or without binding peptides as immunologic carriers for macromolecules |
| US4861798A (en) | 1986-12-29 | 1989-08-29 | Bristol-Myers Company | Lipoxygenase inhibitory compounds |
| US4820828A (en) | 1987-03-04 | 1989-04-11 | Ortho Pharmaceutical Corporation | Cinnamohydroxamic acids |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| ES2008962A6 (es) | 1987-12-17 | 1989-08-16 | Marga Investigacion | Proceso para la preparacion de nuevos compuestos de 2-guanidinotiazol |
| EP0323590A3 (en) | 1987-12-24 | 1990-05-02 | Ono Pharmaceutical Co., Ltd. | Carbazoyl derivatives |
| JPH01224381A (ja) | 1988-03-04 | 1989-09-07 | Japan Tobacco Inc | トリコスタチン酸、トリコスタチンａの新規な合成中間体、及びトリコスタチン酸、トリコスタチンａの製造方法。 |
| EP0347381B1 (de) | 1988-06-13 | 1992-02-12 | Ciba-Geigy Ag | Ungesättigte beta-Ketoesteracetale und ihre Anwendungen |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5175191A (en) | 1988-11-14 | 1992-12-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| AU5927190A (en) | 1989-06-30 | 1991-01-17 | Sloan-Kettering Institute For Cancer Research | Novel potent inducers of terminal differentiation and methods of use thereof |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| EP0502060A4 (en) | 1989-11-13 | 1993-05-05 | Affymax Technologies N.V. | Spatially-addressable immobilization of anti-ligands on surfaces |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| FR2659648B1 (fr) | 1990-03-13 | 1993-02-12 | Michelin Rech Tech | Procede pour preparer un produit aromatique alkyle avec une zeolithe d'alkylation et une zeolithe de dealkylation. |
| JPH0422948A (ja) | 1990-05-18 | 1992-01-27 | Fuji Photo Film Co Ltd | 写真用処理組成物及び処理方法 |
| DE69131509T2 (de) | 1990-05-09 | 1999-11-25 | Fuji Photo Film Co., Ltd. | Photographische Verarbeitungszusammensetzung und diese verwendendes Verarbeitungsverfahren |
| US5045538A (en) | 1990-06-28 | 1991-09-03 | The Research Foundation Of State University Of New York | Inhibition of wasting and protein degradation of mammalian muscle by tetracyclines |
| GB9026114D0 (en) | 1990-11-30 | 1991-01-16 | Norsk Hydro As | New compounds |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| DE69132531T2 (de) | 1990-12-06 | 2001-09-13 | Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) | Verbindungen und ihre Verwendung in einer binären Synthesestrategie |
| EP0501919A1 (de) | 1991-03-01 | 1992-09-02 | Ciba-Geigy Ag | Strahlungsempfindliche Zusammensetzungen auf der Basis von Polyphenolen und Acetalen |
| WO1992015694A1 (en) | 1991-03-08 | 1992-09-17 | The Salk Institute For Biological Studies | Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor |
| US5225173A (en) | 1991-06-12 | 1993-07-06 | Idaho Research Foundation, Inc. | Methods and devices for the separation of radioactive rare earth metal isotopes from their alkaline earth metal precursors |
| EP0603337A1 (en) | 1991-09-13 | 1994-06-29 | New England Deaconess Hospital | Erythropoietin potentiating agents and methods for their use |
| US5700811A (en) | 1991-10-04 | 1997-12-23 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and method of use thereof |
| US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| US5239113A (en) | 1991-10-15 | 1993-08-24 | Monsanto Company | Substituted β-amino acid derivatives useful as platelet aggregation inhibitors and intermediates thereof |
| DE69233501T2 (de) | 1991-11-22 | 2006-02-23 | Affymetrix, Inc. (n.d.Ges.d.Staates Delaware), Santa Clara | Kombinatorische Strategien für die Polymersynthese |
| KR100236806B1 (ko) | 1991-12-10 | 2000-01-15 | 시오노 요시히코 | 방향족 설폰아미드계 하이드록삼산 유도체 |
| US5359115A (en) | 1992-03-26 | 1994-10-25 | Affymax Technologies, N.V. | Methods for the synthesis of phosphonate esters |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| WO1993019778A1 (en) | 1992-04-07 | 1993-10-14 | The Scripps Research Institute | Method for inducing tolerance to an antigen using butyrate |
| JP3356304B2 (ja) | 1992-06-16 | 2002-12-16 | 財団法人生産開発科学研究所 | 抗炎、抗潰瘍剤 |
| US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
| ES2204910T3 (es) | 1992-10-01 | 2004-05-01 | The Trustees Of Columbia University In The City Of New York | Bibliotecas quimicas combinatorias complejas codificadas con señales. |
| EP1362913B1 (en) | 1992-10-30 | 2006-01-25 | The General Hospital Corporation | Interaction trap system for isolating proteins |
| US5480971A (en) | 1993-06-17 | 1996-01-02 | Houghten Pharmaceuticals, Inc. | Peralkylated oligopeptide mixtures |
| US5440016A (en) | 1993-06-18 | 1995-08-08 | Torrey Pines Institute For Molecular Studies | Peptides of the formula (KFmoc) ZZZ and their uses |
| US20030203976A1 (en) | 1993-07-19 | 2003-10-30 | William L. Hunter | Anti-angiogenic compositions and methods of use |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US5362899A (en) | 1993-09-09 | 1994-11-08 | Affymax Technologies, N.V. | Chiral synthesis of alpha-aminophosponic acids |
| US5659016A (en) | 1994-09-22 | 1997-08-19 | Cancer Institute | RPDL protein and DNA encoding the same |
| US6231600B1 (en) | 1995-02-22 | 2001-05-15 | Scimed Life Systems, Inc. | Stents with hybrid coating for medical devices |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US5837313A (en) | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
| JP3330781B2 (ja) | 1995-05-22 | 2002-09-30 | 三菱エンジニアリングプラスチックス株式会社 | ポリカーボネート樹脂組成物 |
| WO1997011366A1 (en) | 1995-09-20 | 1997-03-27 | Merck & Co., Inc. | Histone deacetylase as target for antiprotozoal agents |
| ATE272058T1 (de) | 1995-10-17 | 2004-08-15 | Combichem Inc | Matrize für die synthese kombinatorischer bibliotheken in lösung |
| JPH09124918A (ja) | 1995-10-30 | 1997-05-13 | Mitsubishi Eng Plast Kk | ポリカーボネート樹脂組成物 |
| US6030945A (en) | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
| US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
| US6068987A (en) | 1996-09-20 | 2000-05-30 | Merck & Co., Inc. | Histone deacetylase as target for antiprotozoal agents |
| WO1998016830A2 (en) | 1996-10-16 | 1998-04-23 | The President And Fellows Of Harvard College | Droplet assay system |
| ZA9710342B (en) | 1996-11-25 | 1998-06-10 | Alza Corp | Directional drug delivery stent and method of use. |
| US6273913B1 (en) | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
| NZ500590A (en) | 1997-04-22 | 2001-11-30 | Cocensys Inc | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof |
| AUPO721997A0 (en) | 1997-06-06 | 1997-07-03 | Queensland Institute Of Medical Research, The | Anticancer compounds |
| US6190619B1 (en) | 1997-06-11 | 2001-02-20 | Argonaut Technologies, Inc. | Systems and methods for parallel synthesis of compounds |
| US5891507A (en) | 1997-07-28 | 1999-04-06 | Iowa-India Investments Company Limited | Process for coating a surface of a metallic stent |
| US6195612B1 (en) | 1998-01-05 | 2001-02-27 | Tama L. Pack-Harris | Pharmacy benefit management system and method of using same |
| US6503708B1 (en) | 1998-01-26 | 2003-01-07 | Incyte Genomics, Inc. | Microtubule-associated protein |
| US6428960B1 (en) | 1998-03-04 | 2002-08-06 | Onyx Pharmaceuticals, Inc. | Selection method for producing recombinant baculovirus |
| US6037361A (en) | 1998-03-09 | 2000-03-14 | Warner-Lambert Company | Fluorinated butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
| US6153252A (en) | 1998-06-30 | 2000-11-28 | Ethicon, Inc. | Process for coating stents |
| US6248127B1 (en) | 1998-08-21 | 2001-06-19 | Medtronic Ave, Inc. | Thromboresistant coated medical device |
| DE19846008A1 (de) | 1998-10-06 | 2000-04-13 | Bayer Ag | Phenylessigsäure-heterocyclylamide |
| KR20010080709A (ko) | 1998-12-10 | 2001-08-22 | 프리돌린 클라우스너, 롤란드 비. 보레르 | 프로콜라겐 ｃ-프로티나제 저해제 |
| AU3118200A (en) | 1998-12-14 | 2000-07-03 | Merck & Co., Inc. | Hiv integrase inhibitors |
| WO2000035911A1 (en) | 1998-12-16 | 2000-06-22 | Aventis Pharma Limited | Heteroaryl-cyclic acetals |
| AR035313A1 (es) | 1999-01-27 | 2004-05-12 | Wyeth Corp | Inhibidores de tace acetilenicos de acido hidroxamico de sulfonamida a base de alfa-aminoacidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de medicamentos. |
| US6258121B1 (en) | 1999-07-02 | 2001-07-10 | Scimed Life Systems, Inc. | Stent coating |
| US6203551B1 (en) | 1999-10-04 | 2001-03-20 | Advanced Cardiovascular Systems, Inc. | Chamber for applying therapeutic substances to an implant device |
| KR20020070285A (ko) | 1999-11-23 | 2002-09-05 | 메틸진, 인크. | 히스톤 디아세틸라제의 억제제 |
| US6251136B1 (en) | 1999-12-08 | 2001-06-26 | Advanced Cardiovascular Systems, Inc. | Method of layering a three-coated stent using pharmacological and polymeric agents |
| US6797820B2 (en) | 1999-12-17 | 2004-09-28 | Vicuron Pharmaceuticals Inc. | Succinate compounds, compositions and methods of use and preparation |
| US20030129724A1 (en) | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| GB0023983D0 (en) | 2000-09-29 | 2000-11-15 | Prolifix Ltd | Therapeutic compounds |
| EP1335898B1 (en) | 2000-09-29 | 2005-11-23 | TopoTarget UK Limited | Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
| US6495719B2 (en) | 2001-03-27 | 2002-12-17 | Circagen Pharmaceutical | Histone deacetylase inhibitors |
| AR035455A1 (es) | 2001-04-23 | 2004-05-26 | Hoffmann La Roche | Derivados triciclicos de alquilhidroxamato , procesos para su elaboracion, composiciones farmaceuticas que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos |
| US7244853B2 (en) * | 2001-05-09 | 2007-07-17 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
| WO2002089782A2 (en) | 2001-05-09 | 2002-11-14 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
| US6897220B2 (en) * | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| JP2003221398A (ja) | 2001-11-22 | 2003-08-05 | Japan Science & Technology Corp | 蛍光又は発色基質を用いたヒストンデアセチラーゼ活性測定法 |
| US6517889B1 (en) | 2001-11-26 | 2003-02-11 | Swaminathan Jayaraman | Process for coating a surface of a stent |
| WO2003046207A2 (en) | 2001-11-27 | 2003-06-05 | Fred Hutchinson Cancer Research Center | Methods for inhibiting deacetylase activity |
| US7148257B2 (en) | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
| WO2003075839A2 (en) | 2002-03-04 | 2003-09-18 | Aton Pharma, Inc. | Methods of inducing terminal differentiation |
| EP1362914A3 (en) | 2002-05-15 | 2004-05-06 | Schering AG | Histone deacetylase inhibitor and use thereof |
| JP2004043446A (ja) | 2002-05-15 | 2004-02-12 | Schering Ag | ヒストンデアセチラーゼ抑制剤及びその使用 |
| AU2003249682A1 (en) * | 2002-06-03 | 2003-12-19 | Als Therapy Development Foundation | Treatment of neurodegenerative diseases using proteasome modulators |
| TW200401638A (en) | 2002-06-20 | 2004-02-01 | Bristol Myers Squibb Co | Heterocyclic inhibitors of kinases |
| US6726705B2 (en) | 2002-06-25 | 2004-04-27 | Incisive Surgical, Inc. | Mechanical method and apparatus for bilateral tissue fastening |
| AR043050A1 (es) | 2002-09-26 | 2005-07-13 | Rib X Pharmaceuticals Inc | Compuestos heterociclicos bifuncionales y metodos para preparar y usar los mismos |
| JP2006503082A (ja) | 2002-10-17 | 2006-01-26 | メシルジーン、インコーポレイテッド | ヒストンデアセチラーゼの阻害剤 |
| ES2421516T3 (es) * | 2002-11-06 | 2013-09-03 | Dana Farber Cancer Inst Inc | Composiciones para tratar el cáncer usando el inhibidor de proteasomas PS-341 |
| WO2004046104A2 (en) | 2002-11-20 | 2004-06-03 | Errant Gene Therapeutics, Llc | Treatment of lung cells with histone deacetylase inhibitors |
| CA2851462A1 (en) | 2003-01-08 | 2004-07-29 | University Of Washington | Antibacterial agents |
| US7652036B2 (en) | 2003-02-25 | 2010-01-26 | Topotarget Uk Limited | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors |
| PE20050206A1 (es) | 2003-05-26 | 2005-03-26 | Schering Ag | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa |
| US7842835B2 (en) | 2003-07-07 | 2010-11-30 | Georgetown University | Histone deacetylase inhibitors and methods of use thereof |
| EP1644323B1 (en) | 2003-07-07 | 2015-03-18 | Georgetown University | Histone deacetylase inhibitors and methods of use thereof |
| WO2005012247A1 (en) | 2003-07-30 | 2005-02-10 | Hôpital Sainte-Justine | Compounds and methods for the rapid quantitative analysis of proteins and polypeptides |
| KR100924737B1 (ko) | 2003-08-26 | 2009-11-04 | 슬로안-케테링인스티튜트퍼캔서리서치 | Ｈｄａｃ 억제제를 이용한 암의 치료 방법 |
| EP1541549A1 (en) | 2003-12-12 | 2005-06-15 | Exonhit Therapeutics S.A. | Tricyclic hydroxamate and benzaminde derivatives, compositions and methods |
| US20050137234A1 (en) | 2003-12-19 | 2005-06-23 | Syrrx, Inc. | Histone deacetylase inhibitors |
| JP4989976B2 (ja) | 2004-02-13 | 2012-08-01 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 翻訳開始阻害剤としての３−３−二置換オキシインドール |
| US20060008541A1 (en) | 2004-07-08 | 2006-01-12 | Bizmedic Co., Ltd. | Sodium channel agonist |
| MX2007006523A (es) | 2004-12-03 | 2007-09-11 | Nereus Pharmaceuticals Inc | Metodos para utilizar compuestos heterociclicos [3.2.0] y sus analogos. |
| EP1830838B1 (en) * | 2004-12-03 | 2012-10-03 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating neoplastic diseases |
| CN101495116A (zh) | 2005-03-22 | 2009-07-29 | 哈佛大学校长及研究员协会 | 蛋白降解病症的治疗 |
| US20070062152A1 (en) * | 2005-09-12 | 2007-03-22 | Nokia Corporation | Domesheet assembly in a keyboard |
| TWM290175U (en) * | 2005-09-20 | 2006-05-01 | Chian-Hung Ju | Structure of the light building materials with sound absorption and insulation function |
| US7438916B2 (en) | 2005-10-14 | 2008-10-21 | Virginia Tech Intellectual Properties, Inc. | Therapeutic target for protozoal diseases |
| AU2007214458C1 (en) | 2006-02-14 | 2012-12-06 | Dana-Farber Cancer Institute, Inc. | Histone deacetylase inhibitors |
| AU2007345292B2 (en) | 2006-02-14 | 2013-10-31 | Dana-Farber Cancer Institute, Inc. | Bifunctional histone deacetylase inhibitors |
| CA2647038A1 (en) | 2006-03-22 | 2007-10-04 | The Regents Of The University Of California | Inhibitors of protein prenyltransferases |
| CA2654540C (en) | 2006-05-03 | 2017-01-17 | President And Fellows Of Harvard College | Histone deacetylase and tubulin deacetylase inhibitors |
| US20070282010A1 (en) * | 2006-05-30 | 2007-12-06 | Bridge Pharma, Inc. | Methods of Accelerating Muscle Growth, Decreasing Fat Deposits and Improving Feed Efficiency in Livestock Animals |
| GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| CN101573333B (zh) | 2006-10-28 | 2013-06-12 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
| US8088951B2 (en) | 2006-11-30 | 2012-01-03 | Massachusetts Institute Of Technology | Epigenetic mechanisms re-establish access to long-term memory after neuronal loss |
| EP2209765A4 (en) | 2007-10-22 | 2010-12-01 | Orchid Res Lab Ltd | HISTONE DEACETYLASE INHIBITORS |
| EP2060565A1 (en) | 2007-11-16 | 2009-05-20 | 4Sc Ag | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
| US8467034B2 (en) * | 2008-07-02 | 2013-06-18 | Nikon Corporation | Light shielding unit, variable slit apparatus, and exposure apparatus |
| RU2515611C2 (ru) | 2008-07-23 | 2014-05-20 | Президент Энд Феллоуз Оф Гарвард Колледж | Ингибиторы деацетилазы и их применение |
| EP2334188A4 (en) | 2008-08-15 | 2012-08-08 | Burnham Inst Medical Research | COMPOSITION AND METHOD FOR THE DESIGN AND DEVELOPMENT OF METAL OXYCLES |
| WO2011019393A2 (en) | 2009-08-11 | 2011-02-17 | President And Fellows Of Harvard College | Class- and isoform-specific hdac inhibitors and uses thereof |
| EP2638009A4 (en) | 2010-01-08 | 2014-06-11 | Harvard College | FLUORINATED HDAC HEMMER AND USES THEREOF |
-
2006
- 2006-03-22 CN CNA2006800177289A patent/CN101495116A/zh active Pending
- 2006-03-22 EP EP12150229.8A patent/EP2491926B1/en not_active Expired - Lifetime
- 2006-03-22 EP EP18157889.9A patent/EP3354265A1/en not_active Withdrawn
- 2006-03-22 EP EP06748614A patent/EP1861126A4/en not_active Withdrawn
- 2006-03-22 SG SG201103495-6A patent/SG171690A1/en unknown
- 2006-03-22 WO PCT/US2006/010676 patent/WO2006102557A2/en not_active Ceased
- 2006-03-22 AU AU2006226861A patent/AU2006226861B2/en not_active Ceased
- 2006-03-22 JP JP2008503207A patent/JP5744376B2/ja not_active Expired - Lifetime
- 2006-03-22 US US11/386,959 patent/US8999289B2/en active Active
- 2006-03-22 CA CA2601706A patent/CA2601706C/en not_active Expired - Fee Related
- 2006-03-22 CA CA2937005A patent/CA2937005A1/en not_active Abandoned
-
2012
- 2012-12-05 JP JP2012266681A patent/JP2013053157A/ja not_active Withdrawn
-
2014
- 2014-09-05 JP JP2014180860A patent/JP2014224158A/ja not_active Withdrawn
-
2015
- 2015-04-06 US US14/679,800 patent/US9572854B2/en not_active Expired - Lifetime
-
2017
- 2017-01-09 US US15/401,902 patent/US10172905B1/en not_active Expired - Lifetime
- 2017-07-21 JP JP2017141932A patent/JP2017190338A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009509910A5 (https=) | ||
| CN101133055B (zh) | 用于治疗癌症的meleimide衍生物、药物组合物以及方法 | |
| JP5744376B2 (ja) | タンパク質分解障害の治療 | |
| ES2754221T3 (es) | Compuesto capaz de unirse al receptor de S1P y uso farmacéutico del mismo | |
| Ogden et al. | Let's huddle to prevent a muddle: centrosome declustering as an attractive anticancer strategy | |
| JP7358342B2 (ja) | 新規なグルタミンアンタゴニストおよびそれらの使用 | |
| ES2706066T3 (es) | Procedimiento dirigido a enfermedades mutantes con PTEN y composiciones para las mismas | |
| AU2016326718B2 (en) | Method of screening for agents for differentiating stem cells | |
| Hu et al. | Discovery of a new class of reversible TEA domain transcription factor inhibitors with a novel binding mode | |
| CN101443340A (zh) | 前列腺特异性膜抗原的拟肽抑制剂、含该拟肽抑制剂的化合物及用法 | |
| JP2017190338A5 (https=) | ||
| JP2017501214A (ja) | 治療的な使用のためのｄｏｔａｍ誘導体 | |
| JP2022521452A (ja) | Ｐｉｎ１活性のモジュレータおよびその使用 | |
| US20200405707A1 (en) | Diazinyl amino acridines and medical uses thereof | |
| CA2988421A1 (en) | Small molecule analogs of the nemo binding peptide | |
| MX2011004344A (es) | Terapia contra el cancer. | |
| EP1210098A1 (en) | Enhancement of peptide cellular uptake | |
| WO2008157003A2 (en) | Chemical inhibitors of bfl-1 and related methods | |
| Tabti et al. | Development of prohibitin ligands against osteoporosis | |
| Shukla et al. | A novel peptidomimetic therapeutic for selective suppression of lung cancer stem cells over non-stem cancer cells | |
| AU2015273031B2 (en) | Use of negative functional modulators of erythropoietin for therapy | |
| WO2023001942A1 (en) | 14-3-3 protein modulators as antitumor agents | |
| JP4954888B2 (ja) | グリコーゲンシンターゼキナーゼ−３阻害剤 | |
| Sroka et al. | The minimum element of a synthetic peptide required to block prostate tumor cell migration | |
| CN104159889B (zh) | 介导刺猬蛋白信号通路的新化合物、其标记的形式和应用 |